A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
Latest Information Update: 31 Oct 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms KEYNOTE-087
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 19 Sep 2024 This trial has been completed in Spain (Global end date:2023-09-18) according to European Clinical Trials Database record.
- 29 Sep 2023 Status changed from active, no longer recruiting to completed.
- 15 Jun 2023 Results of post hoc analysis assessing relative efficacy of favezelimab + pembrolizumab (n=27 from MK-4280-003 study) compared with pembrolizumab alone (n=123 from study KEYNOTE 087) in patients with PD-1 refractory R/R cHL presented at the 28th Congress of the European Haematology Association